STOCK TITAN

Interpace Biosciences Inc - IDXG STOCK NEWS

Welcome to our dedicated news page for Interpace Biosciences (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Interpace Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Interpace Biosciences's position in the market.

Rhea-AI Summary
Interpace Biosciences, Inc. announces impressive financial results for Q4 and FY 2023, with revenue reaching $40.2 million, a 26% increase year-over-year. The company reported record test volume, revenue, income, and cash collections, with adjusted EBITDA soaring by 463%. The CEO highlighted the continuous growth and success of the company, attributing it to increased volume, commercial contracts, and collection initiatives. Dr. Nicole Massoll joins as Chief Medical Officer to enhance the company's commitment to providing high-value molecular diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.33%
Tags
-
Rhea-AI Summary
Interpace Biosciences, Inc. (IDXG) announces Q3 revenue of $9.1 million, an 11% increase year-over-year, with a net loss of $0.5 million. The company expects full-year 2023 revenue to exceed $40 million. Q3 test volume and reimbursement also increased by 11% year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Interpace Biosciences Inc

OTC:IDXG

IDXG Rankings

IDXG Stock Data

6.06M
3.35M
25.99%
1.17%
Dental Laboratories
Manufacturing
Link
US
Parsippany

About IDXG

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.